Document Type: Research Articles
Department of Pathology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia.
Pathology Division, School of Medicine, International Medical University, Kuala Lumpur, Malaysia.
Introduction: Vascular endothelial growth factor (VEGF) is an angiogenic factor that plays an important role in
thyroid cancer. VEGF is known to have high affinity to VEGF receptors such as VEGFR-1 (Flt-1) and VEGFR-2 (KDR).
Papillary thyroid carcinoma (PTC) is the most common thyroid cancer and studies showed the increasing incidence of
PTC arising in nodular hyperplasia. Targeted therapy on these growth factors and receptors are used in management
of both differentiated and undifferentiated thyroid carcinoma. This study aims to determine the expression of VEGF
and VEGF receptors (VEGFR) in thyroid nodular hyperplasia and PTC. Methods: A cross-sectional study based on
paraffinized archival tissue blocks of 113 nodular hyperplasias and 67 PTC from the thyroidectomy specimens in
the year of 2003 to 2014. The tissue sections were then stained by immunohistochemistry for VEGF, VEGFR-1 and
VEGFR-2. The lymph node involvement and extrathyroid extension also were determined. Results: The mean age of
PTC patients was 44.7±15.8 years and nodular hyperplasia were 42.2±13.6 years. There was a statistical difference
of VEGFR-1 (p=0.028) and VEGFR-2 (p=0.003) expression between nodular hyperplasia and PTC. However, no
significant difference of VEGF expression (p=0.576) between both diseases. Co-expression of VEGF and VEGFR-1
was significant in both nodular hyperplasia (p=0.016) and PTC (p=0.03), meanwhile no relevant relationship for VEGF
and VEGFR-2 expression (p>0.05). No significant association (p>0.05) between lymph node status and extrathyroid
extension with age groups, gender, VEGF and VEGFR expression. Conclusions: VEGF, VEGFR-1 and VEGFR-2
showed overexpression in both nodular hyperplasia and PTC. The expression of VEGFR-1 and VEGFR-2 are more
significant in PTC with relevant co-expression of VEGF and VEGFR-1. Therefore, the inhibition of VEGFR offers a
promising prospect for tumour management in thyroid carcinoma.